Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 12;10(2):e62.
doi: 10.1192/bjo.2024.13.

Medicinal cannabis for treating post-traumatic stress disorder and comorbid depression: real-world evidence

Michael T Lynskey  1 , Alkyoni Athanasiou-Fragkouli  1 , Hannah Thurgur  1 , Anne Katrin Schlag  1 , David J Nutt  2
Affiliations

Medicinal cannabis for treating post-traumatic stress disorder and comorbid depression: real-world evidence

Michael T Lynskey et al. BJPsych Open. .

Abstract

Background: Cannabis-based medicinal products (CBMPs) are increasingly being used to treat post-traumatic stress disorder (PTSD), despite limited evidence of their efficacy. PTSD is often comorbid with major depression, and little is known about whether comorbid depression alters the effectiveness of CBMPs.

Aims: To document the prevalence of depression among individuals seeking CBMPs to treat PTSD and to examine whether the effectiveness of CBMPs varies by depression status.

Method: Data were available for 238 people with PTSD seeking CBMP treatment (5.9% of the treatment-seeking sample) and 3-month follow-up data were available for 116 of these. Self-reported PTSD symptoms were assessed at treatment entry and at 3-month follow-up using the PTSD Checklist - Civilian Version (PCL-C). The probable presence of comorbid depression at treatment entry was assessed using the nine-item Patient Health Questionnaire (PHQ-9). Additional data included sociodemographic characteristics and self-reported quality of life.

Results: In total, 77% met screening criteria for depression, which was associated with higher levels of PTSD symptomatology (mean 67.8 v. 48.4, F(1,236) = 118.5, P < 0.001) and poorer general health, quality of life and sleep. PTSD symptomatology reduced substantially 3 months after commencing treatment (mean 58.0 v. 47.0, F(1,112) = 14.5, P < 0.001), with a significant interaction (F(1,112) = 6.2, P < 0.05) indicating greater improvement in those with depression (mean difference 15.3) than in those without (mean difference 7).

Conclusions: Depression is common among individuals seeking CBMPs to treat PTSD and is associated with greater symptom severity and poorer quality of life. Effectiveness of CBMPs for treating PTSD does not appear to be impaired in people with comorbid depression.

Keywords: Post-traumatic stress disorder; comorbidity; depressive disorders; medicinal cannabis; treatment outcome.

PubMed Disclaimer

Conflict of interest statement

A.K.S. is scientific advisor to Somai Pharmaceuticals and Evolve. None of the authors would benefit from the wider prescription of medical cannabis in any form.

Figures

Fig. 1
Fig. 1
Estimated marginal means of post-traumatic stress disorder (PTSD) severity by depression status.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lynskey MT, Schlag AK, Athanasiou-Fragkouli A, Badcock D, Nutt DJ. Characteristics of and 3-month health outcomes for people seeking treatment with prescribed cannabis: real-world evidence from project Twenty21. Drug Sci Policy Law 2023; 9: 20503245231167373.
    1. Schlag AK, Lynskey M, Fayaz A, Athanasiou-Fragkouli A, Brandner B, Haja B, et al. Characteristics of people seeking prescribed cannabinoids for the treatment of chronic pain: evidence from Project Twenty 21. Front Pain Res Lausanne 2022; 3: 891498. - PMC - PubMed
    1. Ashare RL, Kelly E, Hajjar ER, Pant S, Meghani SH, Worster B. Characterizing anxiety, pain, sleep, and quality of life among patients in a state medical marijuana program. Complement Ther Clin Pract 2022; 48: 101612. - PubMed
    1. Leung J, Chan G, Stjepanović D, Chung JYC, Hall W, Hammond D. Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada. Psychopharmacology (Berl) 2022; 239: 1509–19. - PMC - PubMed
    1. Mahabir VK, Merchant JJ, Smith C, Garibaldi A. Medical cannabis use in the United States: a retrospective database study. J Cannabis Res 2020; 2(1): 32. - PMC - PubMed